Abstract
The great challenge for oncologists treating patients who are developing or progressing with metastatic disease is to be able to offer a truly personalized and targeted therapy that can have an early and meaningful effect on the course of the disease. At present the known molecular markers are limited in their frequency and reliability in determining the use of newer chemotherapies. Professor Eng discusses the challenges faced in ensuring timely and effective treatments based on the molecular profile of the tumour and the potential role of real-time analysis of mutational changes in the tumour when progression occurs.
| Originalsprog | Engelsk |
|---|---|
| Tidsskrift | Colorectal Disease |
| Vol/bind | 20 |
| Udgave nummer | S4 |
| Sider (fra-til) | 49-51 |
| Antal sider | 3 |
| ISSN | 1463-1318 |
| DOI | |
| Status | Udgivet - 1 maj 2018 |
| Begivenhed | 13th Scientific and Annual Meeting of the European Society of Coloproctology - Acropolis Palais des Congrès, Nice, Frankrig Varighed: 26 sep. 2018 → 28 sep. 2018 Konferencens nummer: 13 https://www.escp.eu.com/conference-and-events/escp-nice-2018/registration-and-fees |
Konference
| Konference | 13th Scientific and Annual Meeting of the European Society of Coloproctology |
|---|---|
| Nummer | 13 |
| Lokation | Acropolis Palais des Congrès |
| Land/Område | Frankrig |
| By | Nice |
| Periode | 26/09/2018 → 28/09/2018 |
| Internetadresse |